The present application relates to a non-human mammal model of a human neurodegenerative disorder, methods of producing the non-human mammal model, and methods of using the non-human mammal model to identify agents suitable for treating a neurodegenerative disorder. The present application also relates to methods of treating neurodegenerative disorders and restoring normal brain interstitial potassium levels.

A method for evaluating biofilm formation on a medical device material in vivo using an invertebrate includes: a step of inserting the medical device material between a hypodermal portion and an intestinal tract of an invertebrate, a step of extracting the medical device material from the invertebrate, and a step of evaluating biofilm formation on the surface of the medical device material; the invertebrate is for use in this evaluation of the biofilm formation.

The present disclosure provides, inter alia, compositions and methods for treating or ameliorating the effects of a tumor in a subject comprising a three-dimensional (3D) organoid system.

The present disclosure provides transgenic non-human animal (e.g., nematode) systems for assessing heterologous polygenic or monogenic phenotypes, their variants and drug discovery. The transgenic non-human animals (e.g., nematodes) contain a first heterologous polypeptide coding sequence and a second heterologous polypeptide coding sequence (a plurality of heterologous polypeptide coding sequences), wherein the first and second heterologous polypeptide coding sequences are integrated into the host animal genome, and wherein expression of the first and second heterologous polypeptide coding sequence contribute to the heterologous phenotype. The plurality of heterologous polypeptide coding sequences are interrelated wherein their expression products, directly or indirectly, contribute or lead to an observable phenotype.

This disclosure relates to methods for screening therapeutic agents to treat altered function of a mutated target gene (e.g., clinical variant) as well as reagents for use in the same.

The present invention relates to methods and compositions for high content drug screening in Caenorhabditis elegans which may be used to identify compounds that treat disorders associated with protein aggregation. It is based, at least in part, on the discovery that Caenorhabditis elegans, genetically modified to create a model system for disorders of protein aggregation, could be used, in a high throughput screening system, to identify agents that reduce the amount of aggregated protein.

The present invention relates to an animal model for oxidative stress research and use thereof, and more specifically, the present invention can utilize a mutant of RCAT having a regulatory function for an antioxidant stress regulator in Caenorhabditis elegans and a human cell line expressing RCAT as animal and human cell line models for oxidative stress research, using the mutant and the human cell line.

The present application relates to a non-human mammal model of a human neurodegenerative disorder, methods of producing the non-human mammal model, and methods of using the non-human mammal model to identify agents suitable for treating a neurodegenerative disorder. The present application also relates to methods of treating neurodegenerative disorders and restoring normal brain interstitial potassium levels.

A microfluidic device capable of trapping contents in a manner suitable for high-throughput imaging is described herein. The microfluidic device may include one or more trapping devices, with each trapping device having a plurality of trapping channels. The trapping channels may be configured to receive contents via an inlet channel that connects a sample reservoir to the trapping channels via fluid communication. The trapping channels are shaped such that contents within the trapping channels are positioned for optimal imaging purposes. The trapping channels are also connect to at least one exit channel via fluid communication. The fluid, and contents within the fluid, may be controlled via hydraulic pressure.

The invention discloses a microfluidic device for the culture, selection and/or analysis of sample organisms such as nematodes, as well as for other biological entities such as for instance animal embryos. The device features reservoirs, culture chambers and smart filtering systems allowing for the selection of specific populations/specimens of sample organisms, thus permitting long-term cultures thereof as well as phenotypic/behavioural analyses. Systems and methods for using the microfluidic device are within the present disclosure as well.